VEON Publishes 2024 Integrated Annual Report Detailing Commitment to Sustainable Growth and Highlighting Robust Financial Performance
Dubai, April 14, 2025: VEON Ltd. (Nasdaq: VEON), a global digital operator ('VEON' or 'the Company', and together with its subsidiaries the 'Group'), today announces the publication of its 2024 Integrated Annual Report ('IAR'), showcasing a year of strong operational and financial performance, and commitment to positive social impact.
The IAR also provides the Company's stakeholders with essential information ahead of the 2025 Annual General Meeting of Shareholders scheduled for May 8, 2025, including a summary of some of our key accomplishments during the 2024 reporting period and details of the Company's corporate governance structure, as well as the Group's unaudited remuneration report for the year ended December 31, 2024.
'Our 2024 Integrated Annual Report demonstrates VEON's commitment to delivering sustainable growth for all stakeholders thorough the transformative power of our digital operators,' said Kaan Terzioglu, CEO of VEON Group. 'It is a privilege to rise to challenge of serving the underserved, to turn this opportunity into growth and to commit to do so while upholding high governance standards. I am delighted to see our operating companies deliver on our promises and build the foundations of our future with investments into talent and augmented intelligence-based solutions that empower our customers.'
Driving digital transformation in our markets and launching AI1440
As of the end of 2024, VEON served 122 million total monthly active users across its digital services portfolio. These services empowered our customers by providing access to financial services, digital information and entertainment as well as digital healthcare and learning opportunities. We also served businesses of all sizes with our enterprise solutions.
In 2024, we also successfully deployed VEON's AI-based solutions and capabilities, including of the launching of Kaz-LLM, a large language model in Kazakhstan. Driven by our AI1440 ambition – creating solutions that augment human capabilities across our markets – VEON's digital operators also introduced other AI-powered consumer and enterprise offers that support financial and digital inclusion and data-driven business decisions.
Commitment to Ukraine
In 2024, VEON and Kyivstar continued their unwavering support for Ukraine, committing USD 1 billion in investments between 2023-2027 to rebuild Ukraine's digital infrastructure, maintain connectivity, and expand essential digital services. Key milestones included partnering with Starlink for satellite-based Direct-to-Cell services, enhancing energy resilience with expanded generator and battery deployments, and securing additional spectrum in the November 2024 auction. Our Ukrainian operating company, Kyivstar, was ranked as Ukraine's top international investor in 2022-2023 by Forbes Ukraine and New Voice of Ukraine, underscoring VEON's commitment to rebuilding infrastructure, broadening digital access, and supporting the country's long-term resilience and development.
Building efficiencies for responsible growth
In 2024, VEON worked on enhancing energy efficiency across its operations. The number of Base Transceiver Stations (BTS) utilizing power-saving technology grew significantly, from around 63 thousand in 2023 to 70 thousand in 2024. We increased the adoption of renewable energy technologies: the number of base stations powered by solar and/or wind energy increased from 993 in 2023 to 1,085 in 2024. Meanwhile, our offices and other building energy consumption decreased by nearly 28%.
VEON also accelerated the execution of its asset-light strategy, enabling market-wide efficiencies in the management of infrastructure assets. We successfully completed the sale of our 49% stake in TNS+, Kazakhstan's wholesale telecommunications infrastructure provider. Additionally, we entered into a strategic partnership with Engro Corporation Limited with respect to the pooling and management of our infrastructure assets, starting in Pakistan.
Streamlining governance
As highlighted in our IAR, in 2024, VEON took steps to improve accessibility for investors and streamline its governance through the consolidation of trading in its shares to the Nasdaq Stock Market in the United States. We also relocated our headquarters to the Dubai International Financial Center, bringing us closer to the Group's operating markets. These steps make VEON the largest Nasdaq-listed company headquartered in Dubai, offering a unique opportunity for global investors interested in frontier market growth opportunities.Investing in people and supporting women's inclusion
In 2024, VEON invested USD 4.4 million into employee training and development, a significant increase from USD 2.6 million spent in 2023, highlighting our commitment to continuous learning and personal development. We developed a series of projects to improve the working conditions of employees and workers in our supply chain. We also launched a new policy for supporting the victims of domestic abuse at the Group level.
In addition, in 2024, we introduced new initiatives aimed at supporting women in the broader communities that we serve as well as within VEON Group's workforce. Women representation in leadership roles increased significantly in various operating companies: in Bangladesh from 20 to 25 percent, in Pakistan from 24 to 29 percent, and in Kyrgyzstan from 38 to 44 percent. Supporting equal opportunities for women in society, Banglalink launched Womentor, a program for female STEM students. Mobilink Microfinance Bank's 'Invisible Heirs' campaign and inheritance calculator, which empower women to claim their rightful inheritance in Pakistan, received numerous international accolades including the 'CMO Marketing Campaign' Award at Global Mobile (GLOMO) Awards during Mobile World Congress 2025.
Solid financial performance
As previously announced with the Company's Fourth Quarter and Full Year 2024 Trading Update, VEON's unaudited financial results indicate solid performance, with Group revenues for FY24 increasing by 8.3% year-on-year Group EBITDA growing by 4.9% year-on-year in reported currency. Demonstrating the role of digital services in the Group's financial growth, direct revenues from digital accounted for 11.5% of Group's total revenues, growing at a rate of 63% year-on-year in reported currency.
For detailed insights into VEON's performance in 2024, visit VEON's 2024 Integrated Annual Report on the company's website: https://www.veon.com/integrated-annual-report-2024/.
About VEON
VEON is a digital operator that provides converged connectivity and digital services to nearly 160 million customers. Operating across six countries that are home to more than 7% of the world's population, VEON is transforming lives through technology-driven services that empower individuals and drive economic growth. VEON is listed on NASDAQ. For more information visit: www.veon.comDisclaimer
The release contains estimates and 'forward-looking statements', within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. These forward-looking statements may be identified by words such as 'may,' 'might,' 'will,' 'could,' 'would,' 'should,' 'expect,' 'plan,' 'anticipate,' 'intend,' 'seek,' 'believe,' 'estimate,' 'predict,' 'potential,' 'continue,' 'contemplate,' 'possible' and other similar words. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, without limitation, statements relating to VEON's plans to implement its strategic priorities and extend its digital experience through under its DO1440 and AI1440 operating models and other development plans and initiatives, the impact of VEON's delisting from Euronext, and VEON's HQ relocation to the Dubai International Financial Centre in the United Arab Emirates. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause VEON's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements in this press release.
Forward-looking statements are inherently subject to risks and uncertainties, many of which VEON cannot predict with accuracy and some of which VEON might not even anticipate. The forward-looking statements contained in this release speak only as of the date of this release. VEON does not undertake to publicly update, except as required by U.S. federal securities laws, any forward-looking statement to reflect events or circumstances after such dates or to reflect the occurrence of unanticipated events. There can be no assurance that the initiatives referred to above will be successful.
Notice to readers: financial information presented
VEON's results and other financial information presented in this press release are, unless otherwise stated, prepared in accordance with International Financial Reporting Standards ('IFRS') based on internal management reporting, are the responsibility of management, and have not been externally audited, reviewed, or verified. The financial information included in this release is preliminary and is based on a number of assumptions that are subject to inherent uncertainties and subject to change. Certain amounts and percentages that appear in this release have been subject to rounding adjustments. As a result, certain numerical figures shown as totals may not be an exact arithmetic aggregation of the figures that precede or follow them. Although we believe the information to be reasonable, actual results may vary from the information contained above and such variations could be material. As such, you should not place undue reliance on this information. This information may not be indicative of the actual results for any future period.
Contact Information
Ana de Kok-Reyes Group Director Financial Control, DE&I and ESG esg@veon.com
Hande Asik Group Director of Communications pr@veon.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
35 minutes ago
- Yahoo
Helius Medical Technologies, Inc. Compliant with Nasdaq Bid Price Rule Listing Criteria
Company previously granted extension until June 30, 2025 to regain compliance with Nasdaq's Equity Rule requirement NEWTOWN, Pa., June 04, 2025 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) ('Helius' or the 'Company'), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced that on June 3, 2025, Helius received formal notice from the Nasdaq Hearings Panel of The Nasdaq Stock Market LLC (the 'Panel') indicating that Helius has evidenced full compliance with the minimum bid price requirement set forth Listing Rules 5550(a)(2) (the 'Bid Price Rule'). The Panel further reminded the Company that it is also required to regain compliance with the equity requirement in Listing Rule 5550(b)(1) (the 'Equity Rule') by June 30, 2025 under the extension previously granted by the Panel. Accordingly, the Nasdaq Listing Qualifications hearing process will remain open until the Company has demonstrated compliance with all of The Nasdaq Stock Market's continued listing requirements. About Helius Medical Technologies, Inc. Helius Medical Technologies is a leading neurotech company in the medical device field focused on neurologic deficits using orally applied technology platform that amplifies the brain's ability to engage physiologic compensatory mechanisms and promote neuroplasticity, improving the lives of people dealing with neurologic diseases. The Company's first commercial product is the Portable Neuromodulation Stimulator (PoNS®). For more information about PoNS or Helius Medical Technologies, visit Cautionary Disclaimer Statement Certain statements in this news release are not based on historical facts and constitute forward-looking statements or forward-looking information within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and Canadian securities laws. All statements other than statements of historical fact included in this news release are forward-looking statements that involve risks and uncertainties. Forward-looking statements are often identified by terms such as 'believe,' 'expect,' 'continue,' 'will,' 'goal,' 'aim' and similar expressions. Such forward-looking statements include, among others, but are not limited to, statements regarding the Company's ability to achieve and maintain compliance with the Nasdaq listing rules. The reader is cautioned not to place undue reliance on any forward-looking statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company assumes no obligation to update any forward-looking statement or to update the reasons why actual results could differ from such statements except to the extent required by law. Investor Relations Contact Philip Trip TaylorGilmartin Groupinvestorrelations@
Yahoo
35 minutes ago
- Yahoo
Avant Technologies and Partner, Ainnova, Finalizing Automated Retinal Camera Prototype Ahead of Full-Scale Development
LAS VEGAS, June 4, 2025 /PRNewswire/ -- Avant Technologies, Inc. (OTCQB: AVAI) ("Avant" or the "Company"), and its JV partner, Ainnova Tech, Inc., (Ainnova), a leading healthcare technology company focused on revolutionizing early disease detection using artificial intelligence (AI), today announced the Company is in the final stages of prototyping its proprietary automated retinal camera. Ainnova's new device will offer users a low cost, easier to use camera that captures images automatically and then uploads those images to the Company's Vision AI software platform, which then produces a "risk report" in mere seconds. Vinicio Vargas, Chief Executive Officer at Ainnova and member of the Board of Directors of the joint venture company, Ai-nova Acquisition Corp., said, "The cost of a fundus camera has always been a barrier to entry into in this market, so our low-cost camera, which is a fraction of the cost of currently available cameras on the market, should allow us to not only enter the market, but to capture a large share of the market. "Another significant advantage will be that our camera will be seamlessly packaged together with our Vision AI platform, allowing us to refer more patients in less time and accurately to medical specialists. Also, one of our objectives is to integrate other technologies to this preventive screening, expanding the scope from only diabetic patients to patients who have other risk factors and want to prevent other diseases from a more complete approach." Vision AI is a powerful cutting-edge, AI-driven platform that can quickly and accurately detect the early markers of a host of diseases by applying AI models to examine imaging data from the eye to expedite earlier detection and allow patients to better manage their disease. The diseases that Vision AI can detect, include diabetic retinopathy, other retinopathies, such as glaucoma, macular edema, age-related macular degeneration, and other anomalies, as well as other diseases that do not require retinal images, and instead, use other datapoints that Ainnova has integrated into the software like the detection of cardiovascular disease (CVD), type 2 diabetes, liver fibrosis, and chronic kidney disease (CKD). Currently, Ainnova's Vision AI software works well with any fundus camera on the market; however, Ainnova and Avant are aiming for exclusivity by developing a lower-cost, easier to use camera. Ai-nova Acquisition Corp. (AAC), the company formed by the partnership between Avant and Ainnova, will develop the retinal cameras as part of the joint venture and licensing deal to facilitate the development of Ainnova's technology portfolio. AAC owns the global licensing rights to develop, maintain, and market Ainnova's technology portfolio. About Ainnova Tech, Inc. Ainnova is a Nevada-based healthtech startup with headquarters in San Jose, Costa Rica, and Houston, Texas. Founded by an experienced and innovative team that is dedicated to leveraging artificial intelligence for early disease detection. Recognized with multiple global awards and renowned partnerships with hospitals and medical device companies, we proudly introduce Vision AI – our cutting-edge platform designed to prevent blindness and detect the early onset of diabetes. Explore how Ainnova is revolutionizing healthcare through advanced technology and proactive solutions. About Avant Technologies, Inc. Avant Technologies, Inc. is an emerging technology company developing solutions in artificial intelligence in healthcare. With a focus on pushing the boundaries of what is possible in AI and machine learning, Avant serves a diverse range of industries, driving progress and efficiency through state-of-the-art technology. More information about Avant can be found at You can also follow us on social media at: Forward-Looking Statements Certain statements contained in this press release may constitute "forward-looking statements." Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact. Actual results may differ materially from those indicated by such forward-looking statements because of various important factors as disclosed in our filings with the Securities and Exchange Commission located at their website ( In addition to these factors, actual future performance, outcomes, and results may differ materially because of more general factors including (without limitation) general industry and market conditions and growth rates, economic conditions, governmental and public policy changes, the Company's ability to raise capital on acceptable terms, if at all, the Company's successful development of its products and the integration into its existing products and the commercial acceptance of the Company's products. The forward-looking statements included in this press release represent the Company's views as of the date of this press release and these views could change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date after the date of the press release. Contact:Avant Technologies, Inc. info@ View original content to download multimedia: SOURCE Avant Technologies Inc.
Yahoo
36 minutes ago
- Yahoo
Sharps Technology Begins Shipments Across Three Customer Orders Under Previously Announced Purchase Agreements
Shipments include initial deliveries of SecureGard™ and SoloGard™ smart safety syringes from its Hungary-based manufacturing facility Deliveries mark the Company's transition to a commercial-stage, revenue-generating company NEW YORK, June 04, 2025 (GLOBE NEWSWIRE) -- Sharps Technology, Inc. (Nasdaq: 'STSS' and 'STSSW') ('Sharps'), an innovative medical device and pharmaceutical packaging company offering patented, best-in-class smart-safety syringe products to the healthcare industry, today announced the initiation of shipments for previously announced purchase orders across three customer orders. These shipments mark the Company's first deliveries of its SecureGard™ and SoloGard™ product lines and its transition to generating commercial revenue. Sharps has initiated shipment of its first commercial order of Sologard under a previously announced $50 million supply agreement with a U.S.-based leader in IV flushing solutions. The delivery includes customized 10mL SoloGard smart safety syringes manufactured at the Company's upgraded facility in Hungary. SoloGard is a specialized, FDA- and WHO-approved smart safety syringe featuring ultra-low waste design, standard luer lock compatibility, and re-use prevention technology. This inaugural $400,000 purchase order marks the beginning of a five-year contract to supply up to 500 million syringes and represents the first revenue-generating shipment under the strategic supply agreement. The manufacturing of SoloGard is supported by advanced molding and automation technologies recently invested in by the Company, enabling Sharps to meet the anticipated increase in demand under the agreement during the second half of 2025. In a separate shipment, Sharps delivered SecureGard smart safety syringes to a Hungarian vaccine provider following a $100,000 purchase order. SecureGard is an FDA- and WHO-approved, CE Mark-certified specialized safety syringe featuring an integrated active recessed safety system, ultra-low waste design, and re-use prevention technology. This marks the customer's first commercial order and reflects growing global demand for Sharps' safety syringe technologies. Combined with the SoloGard order, total purchase commitments reached approximately $500,000, establishing Sharps as a revenue-producing company and supporting its transition to commercial operations. Additionally, Sharps has commenced shipment of 200,000 units of 1mL low dead space syringes to a Swiss-based global provider of cosmetic, dental, and ophthalmic injectable therapies. The syringes will be used in a specialized injection pen for the delivery of Botox and represent the first tranche of a 1-million-unit order. This shipment underscores Sharps' ability to serve diverse therapeutic markets and meet the technical requirements of premium, differentiated injectable delivery platforms. 'These initial shipments mark a key operational milestone as Sharps officially transitions to a commercial-stage company,' stated Robert Hayes, Chief Executive Officer of Sharps Technology. 'For the first time, we are recognizing product revenue across multiple product lines and global markets. This achievement validates years of R&D, strategic planning, and manufacturing investment. We've made significant upgrades to our Hungary-based facility to support these deliveries, including the installation of next-generation molding and automation technologies, to ensure we can meet near-term demand and scale rapidly to fulfill long-term contracts. These enhancements not only increase our production capacity, but also elevate the consistency and quality required by our customers.' All products are being manufactured and shipped from Sharps' facility in Hungary, which has undergone significant upgrades to support high-volume, high-precision production. The Company continues to build inventory and expand capacity to support current and future purchase commitments under long-term strategic agreements. Mr. Hayes concluded: 'Our progress reflects strong execution by the Sharps team and the strategic value of our manufacturing investments. We look forward to deepening relationships with our partners and driving additional growth in the quarters ahead.' About Sharps Technology:Sharps Technology is an innovative medical device and pharmaceutical packaging company offering patented, best-in-class smart-safety syringe products to the healthcare industry. The Company's product lines focus on providing ultra-low waste capabilities, that incorporate syringe technologies that use both passive and active safety features. Sharps also offers products that are designed with specialized copolymer technology to support the prefillable syringe market segment. The Company has a manufacturing facility in Hungary. For additional information, please visit FORWARD-LOOKING STATEMENTS:This press release contains 'forward-looking statements'. Forward-looking statements reflect our current view about future events. When used in this press release, the words 'anticipate,' 'believe,' 'estimate,' 'expect,' 'future,' 'intend,' 'plan,' 'poised' or the negative of these terms and similar expressions, as they relate to us or our management, identify forward-looking statements. Such statements, include, but are not limited to, statements contained in this press release relating to our business strategy, our future operating results and liquidity, and capital resources outlook. Forward-looking statements are based on our current expectations and assumptions regarding our business, the economy, and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks, and changes in circumstances that are difficult to predict. Our actual results may differ materially from those contemplated by the forward-looking statements. They are neither statements of historical fact nor guarantees of assurance of future performance. We caution you therefore against relying on any of these forward-looking statements. Important factors that could cause actual results to differ materially from those in the forward-looking statements include, without limitation, our ability to raise capital to fund continuing operations; our ability to protect our intellectual property rights; the impact of any infringement actions or other litigation brought against us; competition from other providers and products; our ability to develop and commercialize products and services; changes in government regulation; our ability to complete capital raising transactions; and other factors relating to our industry, our operations and results of operations. Actual results may differ significantly from those anticipated, believed, estimated, expected, intended, or planned. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We cannot guarantee future results, levels of activity, performance, or achievements. The Company assumes no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release. Investor Contact:Holdsworth PartnersAdam HoldsworthPhone: 917-497-9287Email: IR@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
